Claire S Philipp1, Ambarina S Faiz2, Michele G Beckman3, Althea Grant3, Paula L Bockenstedt4, John A Heit5, Andra H James6, Roshni Kulkarni7, Marilyn J Manco-Johnson8, Stephan Moll9, Thomas L Ortel10. 1. Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: philipp@rutgers.edu. 2. Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. 3. Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Department of Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 6. Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA. 7. Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA. 8. Department of Pediatrics, University of Colorado, Denver and the Children's Hospital, Aurora, CO, USA. 9. Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 10. Departments of Medicine and Pathology, Duke University, Durham, NC, USA.
Abstract
INTRODUCTION: Black women have an increased risk of adverse pregnancy outcomes and the characteristics of thrombotic risk factors in this population are unknown. The objective of this study was to examine the racial differences in thrombotic risk factors among women with adverse pregnancy outcomes. METHODS: Uniform data were collected in women with adverse pregnancy outcomes (pregnancy losses, intrauterine growth restriction (IUGR), prematurity, placental abruption and preeclampsia) referred to Thrombosis Network Centers funded by the Centers for Disease Control and Prevention (CDC). RESULTS: Among 343 white and 66 black women seen for adverse pregnancy outcomes, protein S and antithrombin deficiencies were more common in black women. The prevalence of diagnosed thrombophilia was higher among whites compared to blacks largely due to Factor V Leiden mutation. The prevalence of a personal history of venous thromboembolism (VTE) did not differ significantly by race. A family history of VTE, thrombophilia, and stroke or myocardial infarction (MI) was higher among whites. Black women had a higher body mass index, and a higher prevalence of hypertension, while the prevalence of sickle cell disease was approximately 27 fold higher compared to the general US black population. CONCLUSIONS: Thrombotic risk factors differ significantly in white and black women with adverse pregnancy outcomes. Such differences highlight the importance of considering race separately when assessing thrombotic risk factors for adverse pregnancy outcomes.
INTRODUCTION: Black women have an increased risk of adverse pregnancy outcomes and the characteristics of thrombotic risk factors in this population are unknown. The objective of this study was to examine the racial differences in thrombotic risk factors among women with adverse pregnancy outcomes. METHODS: Uniform data were collected in women with adverse pregnancy outcomes (pregnancy losses, intrauterine growth restriction (IUGR), prematurity, placental abruption and preeclampsia) referred to Thrombosis Network Centers funded by the Centers for Disease Control and Prevention (CDC). RESULTS: Among 343 white and 66 black women seen for adverse pregnancy outcomes, protein S and antithrombin deficiencies were more common in black women. The prevalence of diagnosed thrombophilia was higher among whites compared to blacks largely due to Factor V Leiden mutation. The prevalence of a personal history of venous thromboembolism (VTE) did not differ significantly by race. A family history of VTE, thrombophilia, and stroke or myocardial infarction (MI) was higher among whites. Black women had a higher body mass index, and a higher prevalence of hypertension, while the prevalence of sickle cell disease was approximately 27 fold higher compared to the general US black population. CONCLUSIONS:Thrombotic risk factors differ significantly in white and black women with adverse pregnancy outcomes. Such differences highlight the importance of considering race separately when assessing thrombotic risk factors for adverse pregnancy outcomes.
Authors: Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: N F Dowling; M G Beckman; M Manco-Johnson; K Hassell; C S Philipp; L A Michaels; S Moll; J A Heit; J Penner; R Kulkarni; S Pipe; P Bockenstedt; J Andersen; S Crudder; A H James; S Zimmerman; T L Ortel Journal: J Thromb Thrombolysis Date: 2007-02 Impact factor: 2.300
Authors: Willem J Kist; Nard G Janssen; Jakoba J Kalk; William M Hague; Gustaaf A Dekker; Johanna I P de Vries Journal: Thromb Haemost Date: 2008-01 Impact factor: 5.249
Authors: Daniel Landi; Michele G Beckman; Nirmish R Shah; Paula Bockenstedt; Althea M Grant; John A Heit; Nigel S Key; Roshni Kulkarni; Marilyn Manco-Johnson; Stephan Moll; Claire S Philipp; Judith C Andersen; Thomas L Ortel Journal: Thromb Haemost Date: 2013-02-14 Impact factor: 5.249
Authors: J A Lykke; L A Bare; J Olsen; R Lagier; A R Arellano; C Tong; M J Paidas; J Langhoff-Roos Journal: J Thromb Haemost Date: 2012-07 Impact factor: 5.824
Authors: Robert M Silver; Yuan Zhao; Catherine Y Spong; Baha Sibai; George Wendel; Katharine Wenstrom; Philip Samuels; Steve N Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner Journal: Obstet Gynecol Date: 2010-01 Impact factor: 7.623